A new study found that awareness of biosimilars is low in terms of safety, efficacy, and access to these agents. Just six percent of the general population reported at least a general impression of biosimilars, while awareness was higher (20 to 30 percent) among patients with diseases such as rheumatoid arthritis and psoriasis who participate in patient support groups. The researchers concluded that there’s an immediate need for patient education about biosimilars to ensure educated and informed decisions are made about their use.

Click here for more